These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 34289398)

  • 21. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
    Mordi IR; Lang CC
    Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
    Salvatore T; Galiero R; Caturano A; Rinaldi L; Di Martino A; Albanese G; Di Salvo J; Epifani R; Marfella R; Docimo G; Lettieri M; Sardu C; Sasso FC
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes.
    Jones NK; Costello HM; Monaghan MT; Stewart K; Binnie D; Marks J; Bailey MA; Culshaw GJ
    Exp Physiol; 2023 Mar; 108(3):480-490. PubMed ID: 36644793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
    Wu VC; Li YR; Wang CY
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
    Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
    Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes.
    Čertíková Chábová V; Zakiyanov O
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis.
    Onoue T; Kataoka M
    Clin Drug Investig; 2022 Dec; 42(12):1025-1030. PubMed ID: 36344670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences.
    Dominguez Rieg JA; Xue J; Rieg T
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):523-530. PubMed ID: 32701600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.